Description

Lofexidine Hydrochloride

Lofexidine Hydrochloride is a high-purity, centrally acting α₂-adrenergic receptor agonist used in pharmaceutical formulations for the mitigation of opioid withdrawal symptoms. It is a non-opioid active pharmaceutical ingredient (API) that reduces sympathetic outflow and helps alleviate autonomic symptoms during detoxification and medication-assisted treatment (MAT). Lofexidine Hydrochloride is

• A centrally acting α₂-adrenergic agonist for opioid withdrawal management
• A non-opioid API with minimal abuse potential
• Suitable for oral solid dosage forms including tablets and capsules
• Used in medication-assisted detoxification protocols
• Manufactured under Good Manufacturing Practice (GMP) conditions
• Supplied with complete regulatory documentation including Certificate of Analysis (CoA), DMF, and supporting technical data

Lofexidine Hydrochloride is chemically designated as 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole hydrochloride. It acts on presynaptic α₂A-adrenergic receptors in the brainstem, decreasing norepinephrine release and mitigating withdrawal symptoms such as anxiety, sweating, gastrointestinal distress, and tachycardia.

In pharmaceutical applications, Lofexidine Hydrochloride is used in:

• Medication-assisted treatment (MAT) for opioid detox and tapering support
• Short-term use in inpatient or outpatient detox programs to ease acute withdrawal
• Adjunct therapy with non-opioid medications in relapse prevention strategies
• Research and development in autonomic regulation, addiction medicine, and psychiatry

Lofexidine has a favorable safety profile and is typically well tolerated. Unlike Clonidine, it offers selective α₂A binding, which reduces risks of hypotension and sedation. It is approved in several markets as a prescription therapy for managing acute opioid withdrawal symptoms.

CarboMer supplies Lofexidine Hydrochloride with tight control over assay, enantiomeric purity, residual solvents, and microbial load. Material is manufactured under GMP-compliant conditions and is suitable for inclusion in regulated oral dosage forms.

The material is packaged in sealed, light-protective, tamper-evident containers. Available in R&D, pilot, and commercial quantities. Minimum order quantities (MOQ), lead times, and documentation including CoA, SDS, and regulatory DMF access are provided upon request.

Each batch is tested for identity (IR, HPLC), assay, related substances, optical rotation, heavy metals, and microbial purity. Certificates of Analysis (CoA), Safety Data Sheets (SDS), and full traceability documentation accompany every shipment.

As with all CarboMer CNS-active APIs, Lofexidine Hydrochloride is supported by formulation expertise, regulatory strategy, and secure global sourcing to help you deliver effective therapies for opioid use disorder and withdrawal management.